A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters

Human Psychopharmacology
Paolo LeombruniSecondo Fassino

Abstract

Previous studies tested the efficacy of sertraline in Binge Eating Disorder (BED) over a period of 6 weeks. The present open study assesses the efficacy of sertraline over a period of 24 weeks in obese persons with binge eating behaviour (with or without the full criteria for BED) confirmed by high scores on the Binge Eating Scale (BES). Thirty-two obese outpatients (14 with BED and 18 without full criteria for BED), without co-occurring psychiatric comorbidities, were treated with sertraline (dose range 100-200 mg/d). Subjects were assessed at baseline and at 8, 12 and 24 weeks of treatment for number of binges, weight and psychopathology. After 8 weeks of treatment a significant improvement in the BES score and a significant weight loss emerged. These results were maintained over 24 weeks. A moderate drop out rate was detected, but no significant association with the severity of side effects was found. Further studies are needed to confirm the usefulness of sertraline in the treatment of patients with BED and also in binge eaters with a less severe eating psychopathology.

References

Jan 1, 1982·Addictive Behaviors·J GormallyD Rardin
Jan 1, 1994·The International Journal of Eating Disorders·M de ZwaanR B Crosby
Dec 1, 1996·Journal of Endocrinological Investigation·V RiccaC M Rotella
Apr 20, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S A Montgomery
Jun 1, 2000·The American Journal of Psychiatry·S L McElroyJ I Hudson
Oct 31, 2000·The International Journal of Eating Disorders·R J Milligan, G Waller
Oct 5, 2002·The Journal of Clinical Psychiatry·Shishuka MalhotraSusan L McElroy
Nov 20, 2002·Comprehensive Psychiatry·Secondo FassinoGiovanni Giacomo Rovera
Apr 30, 2003·Archives of Women's Mental Health·T PearlsteinM B Keller
Jun 5, 2003·Journal of Psychosomatic Research·Secondo FassinoGiovanni Giacomo Rovera
Aug 6, 2003·The International Journal of Eating Disorders·Michael J DevlinIlyse Dobrow
Aug 6, 2003·The International Journal of Eating Disorders·William P CarterHarrison G Pope
Jan 6, 2004·The International Journal of Eating Disorders·John P O'ReardonKelly C Allison
Apr 3, 2004·Current Drug Targets·Jose C Appolinario, Susan L McElroy
Sep 11, 2004·Journal of Psychopharmacology·Secondo FassinoAndrea Pierò
Apr 28, 2005·The International Journal of Eating Disorders·Carlos M GriloBruce S Rothschild

❮ Previous
Next ❯

Citations

Jul 19, 2008·Advances in Therapy·Paolo LeombruniSecondo Fassino
Mar 29, 2008·Annual Review of Clinical Psychology·Ruth H Striegel-Moore, Debra L Franko
Aug 4, 2009·Neuropsychiatric Disease and Treatment·Paolo LeombruniSecondo Fassino
Jun 2, 2012·Therapeutics and Clinical Risk Management·Susan L McElroyAnne M O'Melia
Jul 5, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Paolo LeombruniSecondo Fassino
Jun 19, 2009·Human Psychopharmacology·Paolo LeombruniSecondo Fassino
Jan 30, 2015·Journal of Addiction Medicine·Arianna GoracciAndrea Fagiolini

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.